A video interview with  James C. Shehan, Chair of Lowenstein’s FDA Regulatory practice, on the FDA’s new approach to citizen petitions aimed at delaying market entry of products, was published on the CenterForBiosimilars.com. Shehan explains that the agency has issued more details on the criteria it will use in deciding whether a petition’s primary purpose is to delay generic competition.